Suppr超能文献

中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、淋巴细胞与单核细胞比值及血小板在前列腺癌患者预后中的作用。

Role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer.

作者信息

Huszno Joanna, Kołosza Zofia, Mrochem-Kwarciak Jolanta, Telka Ewa, Jochymek Bożena, Miszczyk Leszek

机构信息

Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-100 Gliwice, Poland.

Genetic Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-100 Gliwice, Poland.

出版信息

Oncol Lett. 2022 Jul 8;24(3):305. doi: 10.3892/ol.2022.13425. eCollection 2022 Sep.

Abstract

The aim of the present analysis was to evaluate the platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelets (PLT) and neutrophil level for their prognostic values in patients with prostate cancer who had been treated with radiotherapy. A retrospective analysis of 152 patients who were treated in the Radiotherapy Department at Maria Sklodowska-Curie National Research Institute of Oncology (Gliwice, Poland) between January 2012 and December 2014 was performed. The prognostic value (overall survival; OS) of the pre-treatment PLR, NLR, LMR, PLT, neutrophil level and other laboratory factors such as: leukocyte, lymphocyte, monocyte, hemoglobin, RBC, prostate-specific antigen level (PSA), Gleason score, age, smoking and comorbid condition were assessed using univariate analysis. The cut-off point was determined for NLR as 'elevated' at >4.66, LMR >3.26 and the PLR was considered 'elevated' at >89.6. Median follow-up was 4.9 years. The 5 and 7-year OS rates were 81.5 and 72.2%, respectively. In univariate analysis higher NLR (P=0.007), higher level of PLT (P=0.004), higher level of neutrophils (P=0.013), elevated level of leukocyte (P=0.043) and lymphocyte (P=0.043) were factors significantly associated with decreased OS. No difference was found for PLR (P=0.308) and LMR (P=0.109). The other factor associated with decreased OS were: higher Gleason score (>7; P=0.005), higher PSA level (>20 ng/dl; P=0.0001), smoking (P=0.003) and older age (>70 years; P=0.018). In multivariate analysis, NLR, LMR, leukocyte and RBC were independently associated with prognosis in patients with prostate cancer. Elevated pre-treatment NLR [hazard ratio (HR)=10.83; P=0.001), LMR (HR=3.14; P=0.007) and higher leukocyte level (HR=3.14; P=0.007) were independently associated with increased mortality risk. Overall, pre-treatment NLR, PLR, leukocyte and RBC levels were revealed to be independent prognostic factors.

摘要

本分析的目的是评估血小板淋巴细胞比率(PLR)、中性粒细胞淋巴细胞比率(NLR)、淋巴细胞单核细胞比率(LMR)、血小板(PLT)和中性粒细胞水平对接受放疗的前列腺癌患者的预后价值。对2012年1月至2014年12月期间在玛丽亚·斯克洛多夫斯卡-居里国家肿瘤研究所放疗科(波兰格利维采)接受治疗的152例患者进行了回顾性分析。采用单因素分析评估治疗前PLR、NLR、LMR、PLT、中性粒细胞水平及其他实验室因素(如白细胞、淋巴细胞、单核细胞、血红蛋白、红细胞、前列腺特异性抗原水平(PSA)、Gleason评分、年龄、吸烟和合并症)的预后价值(总生存期;OS)。确定NLR的截断点为>4.66时“升高”,LMR>3.26时“升高”,PLR>89.6时被认为“升高”。中位随访时间为4.9年。5年和7年总生存率分别为81.5%和72.2%。在单因素分析中,较高的NLR(P=0.007)、较高的PLT水平(P=0.004)、较高的中性粒细胞水平(P=0.013)、升高的白细胞水平(P=0.043)和淋巴细胞水平(P=0.043)是与总生存期降低显著相关的因素。PLR(P=0.308)和LMR(P=0.109)未发现差异。与总生存期降低相关的其他因素包括:较高的Gleason评分(>7;P=0.005)、较高的PSA水平(>20 ng/dl;P=0.0001)、吸烟(P=0.003)和老年(>70岁;P=0.018)。在多因素分析中,NLR、LMR、白细胞和红细胞与前列腺癌患者的预后独立相关。治疗前升高的NLR[风险比(HR)=10.83;P=0.001]、LMR(HR=3.14;P=0.007)和较高的白细胞水平(HR=3.14;P=0.007)与死亡风险增加独立相关。总体而言,治疗前NLR、PLR、白细胞和红细胞水平被揭示为独立的预后因素。

相似文献

6
Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients.
Oncol Lett. 2019 Dec;18(6):6275-6283. doi: 10.3892/ol.2019.10966. Epub 2019 Oct 8.

引用本文的文献

3
Diagnostic Stratification of Prostate Cancer Through Blood-Based Biochemical and Inflammatory Markers.
Diagnostics (Basel). 2025 May 30;15(11):1385. doi: 10.3390/diagnostics15111385.
5
The role of neutrophils and their immunosuppressive effects on prostate cancer.
Histol Histopathol. 2025 Sep;40(9):1347-1353. doi: 10.14670/HH-18-890. Epub 2025 Feb 20.
7
High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations.
Cancer Control. 2024 Jan-Dec;31:10732748241288106. doi: 10.1177/10732748241288106.
10
Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Am J Mens Health. 2024 Mar-Apr;18(2):15579883241234747. doi: 10.1177/15579883241234747.

本文引用的文献

2
Epidemiology of Prostate Cancer.
World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
5
Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis.
Medicine (Baltimore). 2018 Oct;97(40):e12504. doi: 10.1097/MD.0000000000012504.
6
Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer.
Oncotarget. 2017 Aug 10;8(41):70874-70882. doi: 10.18632/oncotarget.20147. eCollection 2017 Sep 19.
7
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.
J Inflamm (Lond). 2016 Nov 25;13:35. doi: 10.1186/s12950-016-0143-2. eCollection 2016.
8
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis.
Medicine (Baltimore). 2016 Jan;95(3):e2544. doi: 10.1097/MD.0000000000002544.
10
The platelet-cancer loop.
Eur J Intern Med. 2013 Jul;24(5):393-400. doi: 10.1016/j.ejim.2013.01.017. Epub 2013 Feb 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验